#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lung adenocarcinoma Hepatic cirrhosis Fatty acid oxidation disorder Factor VIII deficiency Endometrial adenocarcinoma CDKL5 deficiency disorder Haemophilia A without inhibitors Marginal zone lymphoma recurrent Neurotrophic keratopathy Myasthenia gravis Palmoplantar pustulosis Myeloid leukaemia Hepatic angiosarcoma Cerebral arteriovenous malformation haemorrhagic Ischaemic stroke More trials…

    Learn about Rare Diseases

    Primary mediastinal large B-cell lymphoma – Diagnostics Urea cycle disorder – Life with Disease Niemann-Pick disease – Diagnostics Haemolytic uraemic syndrome Ehlers-Danlos syndrome – Life with Disease Bronchiolitis obliterans syndrome – Basic Information Loeys-Dietz syndrome – Trials in Disease Hereditary neuropathic amyloidosis Osteosarcoma Fragile X syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxybuprocaine Hydrochloride Avacincaptad Pegol Inclisiran The-630 99MTC-EUK-(SO3)CY5-MAS3 Amisulpride Deucravacitinib GSKVX000000034797 Hct116-A Cdr132L Sodium Tislelizumab SAR444336 Dinutuximab Beta Izaflortaucipir (18F) Ide397 Erythromycin IHMA-2121908-1 Sodium Butyrate Ibrexafungerp Octreotide Acetate More therapies…

    Learn about Your Condition

    Nephrolithiasis Glomerulonephritis membranous Cervix carcinoma recurrent Glomerulonephritis chronic Circulatory collapse Glomerulonephritis Glycogen storage disorder Von Hippel-Lindau disease Ventricular fibrillation Vitamin D deficiency Anal cancer recurrent Mast cell activation syndrome Glioma Renal disorder Uterine leiomyoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myelodysplastic syndrome

  • Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    • Anaemia
    Investigated Drugs:
    • 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
    France Germany Italy Poland Spain

  • Study on Canakinumab for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes or MDS/MPN

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    • Anaemia
    Investigated Drugs:
    • Canakinumab
    Germany

  • Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Luspatercept
    • Epoetin Alfa
    Czechia France Germany Greece Hungary Italy +2

  • Study of MP0533 for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Using Sodium Dihydrogen Phosphate Dihydrate, Polysorbate 20, and Sodium Chloride

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • ANTIBODY MIMETIC PROTEIN BINDING TO T CELLS CD3, TUMOR-ASSOCIATED ANTIGENS CD70, CD33, CD123, AND HUMAN SERUM ALBUMIN
    • Azacitidine
    • Venetoclax
    France Lithuania The Netherlands

  • Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Azacitidine
    • Venetoclax
    Austria Belgium Czechia France Germany Italy +3

  • Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    • Acute myeloid leukaemia
    Investigated Drugs:
    • 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
    France Italy Poland Spain
Previous Page
1 … 5 6 7 8 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!